Literature DB >> 8551604

The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication.

K de Vreese1, V Kofler-Mongold, C Leutgeb, V Weber, K Vermeire, S Schacht, J Anné, E de Clercq, R Datema, G Werner.   

Abstract

Bicyclams are a novel class of antiviral compounds which act as potent and selective inhibitors of the replication of human immunodeficiency virus type 1 (HIV-1) and HIV-2. They block an early step in the viral life cycle following adsorption to the CD4 receptor and preceding reverse transcription. To identify the molecular target of these compounds, we genetically analyzed variants of the HIV-1 molecular clone NL4-3, which developed resistance against two structurally related bicyclams, JM2763 and the more potent SID791. The resistant strains were obtained after long-term passaging in MT-4 cells in the presence of progressively increasing compound concentrations. Recombinants between selected genes of the resistant strains and the parental NL4-3 provirus were generated by adapting the marker rescue technique to MT-4 cells. The bicyclam-resistant phenotype was rescued by transferring the envelope gp120 gene of bicyclam-resistant virus into the NL4-3 parental genetic background. In the gp120 genes of the resistant strains, we identified several mutations leading to amino acid substitutions in the V3 loop. Furthermore, two substitutions of highly conserved amino acids in close proximity to the disulfide bridges of the V3 and V4 loops were found in both SID791- and JM2763-resistant strains. Additional mutations in regions encoding V3, C4, V5, and C5 were present in SID791-resistant viruses. Recombination experiments with overlapping parts of the envelope gene indicated that most, if not all, of the mutations were necessary to develop the fully SID791 resistant phenotype. The mutations in the C-terminal part of gp120 downstream of the V3 loop sequence conferred partial resistance to JM2763 but did not significantly decrease susceptibility to SID791. The genetic data and the biological properties of the resistant viruses point to inhibition of entry and fusion as the mode of action of the HIV-inhibitory bicyclams. A possible mechanism of binding of bicyclams to gp120 leading to inhibition of unfolding of gp120 and its shedding from the gp41 fusion domain is discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8551604      PMCID: PMC189868          DOI: 10.1128/JVI.70.2.689-696.1996

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.

Authors:  J M Coffin
Journal:  Science       Date:  1995-01-27       Impact factor: 47.728

2.  The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides.

Authors:  D Batinić; F A Robey
Journal:  J Biol Chem       Date:  1992-04-05       Impact factor: 5.157

3.  Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event.

Authors:  E De Clercq; N Yamamoto; R Pauwels; M Baba; D Schols; H Nakashima; J Balzarini; Z Debyser; B A Murrer; D Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

4.  In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase.

Authors:  J W Mellors; G E Dutschman; G J Im; E Tramontano; S R Winkler; Y C Cheng
Journal:  Mol Pharmacol       Date:  1992-03       Impact factor: 4.436

5.  Investigations into the mechanism by which sulfated polysaccharides inhibit HIV infection in vitro.

Authors:  M O McClure; J P Moore; D F Blanc; P Scotting; G M Cook; R J Keynes; J N Weber; D Davies; R A Weiss
Journal:  AIDS Res Hum Retroviruses       Date:  1992-01       Impact factor: 2.205

6.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

7.  Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.

Authors:  H Jacobsen; K Yasargil; D L Winslow; J C Craig; A Kröhn; I B Duncan; J Mous
Journal:  Virology       Date:  1995-01-10       Impact factor: 3.616

8.  Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker.

Authors:  G J Bridger; R T Skerlj; D Thornton; S Padmanabhan; S A Martellucci; G W Henson; M J Abrams; N Yamamoto; K De Vreese; R Pauwels
Journal:  J Med Chem       Date:  1995-01-20       Impact factor: 7.446

9.  Local and global structural properties of the HIV-MN V3 loop.

Authors:  P Catasti; J D Fontenot; E M Bradbury; G Gupta
Journal:  J Biol Chem       Date:  1995-02-03       Impact factor: 5.157

10.  Viral dynamics in human immunodeficiency virus type 1 infection.

Authors:  X Wei; S K Ghosh; M E Taylor; V A Johnson; E A Emini; P Deutsch; J D Lifson; S Bonhoeffer; M A Nowak; B H Hahn
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

View more
  37 in total

1.  HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use.

Authors:  Alexandra Trkola; Shawn E Kuhmann; Julie M Strizki; Elizabeth Maxwell; Tom Ketas; Tom Morgan; Pavel Pugach; Serena Xu; Lisa Wojcik; Jayaram Tagat; Anandan Palani; Sherry Shapiro; John W Clader; Stuart McCombie; Gregory R Reyes; Bahige M Baroudy; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

2.  Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication.

Authors:  Frauke Christ; Arnout Voet; Arnaud Marchand; Stefan Nicolet; Belete A Desimmie; Damien Marchand; Dorothée Bardiot; Nam Joo Van der Veken; Barbara Van Remoortel; Sergei V Strelkov; Marc De Maeyer; Patrick Chaltin; Zeger Debyser
Journal:  Nat Chem Biol       Date:  2010-05-16       Impact factor: 15.040

3.  Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41.

Authors:  B Labrosse; O Pleskoff; N Sol; C Jones; Y Hénin; M Alizon
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Thymic pathogenicity of an HIV-1 envelope is associated with increased CXCR4 binding efficiency and V5-gp41-dependent activity, but not V1/V2-associated CD4 binding efficiency and viral entry.

Authors:  Eric G Meissner; Vernon M Coffield; Lishan Su
Journal:  Virology       Date:  2005-06-05       Impact factor: 3.616

5.  Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.

Authors:  Daisuke Nameki; Eiichi Kodama; Mieko Ikeuchi; Naoto Mabuchi; Akira Otaka; Hirokazu Tamamura; Mutsuhito Ohno; Nobutaka Fujii; Masao Matsuoka
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure.

Authors:  R Arakaki; H Tamamura; M Premanathan; K Kanbara; S Ramanan; K Mochizuki; M Baba; N Fujii; H Nakashima
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

7.  T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use.

Authors:  D Schols; J A Esté; C Cabrera; E De Clercq
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

8.  Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles.

Authors:  O Hantz; C Borel; C Trabaud; F Zoulim; J Dessolin; M Camplo; P Vlieghe; M Bouygues; C Trepo; J L Kraus
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

9.  Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection.

Authors:  Jan Balzarini; Sigrid Hatse; Kurt Vermeire; Katrien Princen; Stefano Aquaro; Carlo-Federico Perno; Erik De Clercq; Herman Egberink; Guy Vanden Mooter; Willy Peumans; Els Van Damme; Dominique Schols
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry.

Authors:  R Datema; L Rabin; M Hincenbergs; M B Moreno; S Warren; V Linquist; B Rosenwirth; J Seifert; J M McCune
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.